Facult� de m�decine et des sciences de la sant�

Clinical Research

The Division of Rheumatology is currently active in multiple areas of clinical research, including industry-supported multicentric studies, original industry-supported studies, as well as original peer-supported translational studies, whose aims are to evaluate in the clinical situation the validity of observations originating from our local program of fundamental research. The studies currently ongoing are in the following areas/groups of patients:


- Recent-onset polyarthritis (EUPA) (supported by The Arthritis Society): a longitudinal observational cohort study of patients with less than one year of duration of arthritis. The objectives are to define the role of autoantibodies (alone and in combination with genetic and psychosocial determinants) as markers of severity of disease, and to define prognostic models to identify early on patients with the most severe prognosis as well as patients with the best outcomes.


- Role of the osteoclast in Osteoarthritis and in Rheumatoid Arthritis (OPRA) (supported by the Canadian Institutes for Health Research; CIHR): a multicentre and exhaustive study of osteoclasts biogenesis and characteristics in a transversal and longitudinal study of patients with rheumatoid arthritis and of patients with osteoarthritis.


- Treating osteoporosis following fragility fractures at the CHUS (OPTIMUS; joint proposal by the Rheumatology and Orthopedics Divisions of the CHUS) (supported by Merck Frosst Canada and the Alliance for Better Bone Health): identifying the most effective intervention allowing identification of osteoporosis, appropriate investigation, initiation of treatment and increase in long-term adherence among patients presenting to orthopedists with fragility fractures

- The consequences of adding an anti-TNF treatment (adalimumab) on the osteoclastogenesis in patients with active rheumatoid arthritis


- Systemic lupus erythematosus(SLE) (the GENES study of the CaNIOS network): identifying genetic and environmental determinants of the development of SLE.


- Systemic lupus erythematosus (SLE) (in collaboration with HemaQuébec): the influence of IVIg on the production of autoantibodies by B lymphocytes of SLE patients


- Juvenile Idiopathic Arthritis (JIA) (REACCH-OUT and BBOP studies; both supported by the CIHR): defining the incidence and outcomes of JIA in Canada and defining biologic determinants of the outcomes of the more severe forms of JIA


- Systemic Sclerosis: a registry of the patients with systemic sclerosis from across Canada


- Rheumatoid Arthritis: long-term studies on the role of abatacept (Bristol Myers Squibb), rituximab (Hoffman LaRoche), and ocrelizumab (Hoffman LaRoche) in patients unresponsive to methotrexate and/or anti-TNF agents.


- The role of abatacept and rituximab in methotrexate-naïve patients with recent-onset of rheumatoid arthritis.


- Osteoarthritis


- Non steroidal anti-inflammatory drugs